Results 181 to 190 of about 5,478,695 (241)
Veterinary and Comparative Oncology, EarlyView.ABSTRACT Companion canines need advances in therapeutic options for solid tumour malignancies. Natural killer (NK) cell infusions offer a promising treatment modality in canines with solid tumours. Autologous natural killer products are limited by dysfunctional immunity and a manufacturing process that delays care whereas allogeneic NK cells offer the ...
Allison M. Weisnicht +11 more
wiley +1 more source
The Journal of Physiology, EarlyView.Abstract figure legend CAF origins and plasticity give rise to distinct phenotypes with immunosuppressive functions in colorectal cancer and multiple myeloma. These distinct CAF phenotypes contribute to immunosuppressive tumour microenvironments through ECM remodelling, cytokine signalling and immune regulation.
Hui Mo +4 more
wiley +1 more source
Computational and Systems Oncology, Volume 6, Issue 1, December 2026.ABSTRACT Cadherin 1 (CDH1) encodes E‐cadherin, a key epithelial adhesion molecule traditionally associated with tumor suppression and epithelial–mesenchymal transition (EMT). However, its roles across cancers remain incompletely understood, particularly within multilayer regulatory contexts involving genomic, epigenetic, transcriptional, and immune ...
Md. Abdur Rahman +2 more
wiley +1 more source
Red Fluorescent Labeling of Myelin by Membrane‐Targeted tdTomato in Transgenic Mouse Lines
Glia, Volume 74, Issue 12, December 2026.Transgenic mouse lines expressing membrane‐targeted tdTomato in myelin enable imaging of myelin in the red spectral range. Distinct expression patterns range from wide‐spread labeling to sparse single‐cell resolution, supporting diverse imaging applications.
Anja Reinert +15 more
wiley +1 more source
Synergistic Regulation of Biomaterials and Macrophages: A Novel Paradigm in Immunotherapy
MedComm – Biomaterials and Applications, Volume 5, Issue 4, December 2026.Bioengineered materials mediating the modulation of macrophage plasticity and inflammatory signals in the tumor microenvironment effectively remodel immunoregulatory states, boost antitumor immunity, and promote tissue repair, achieving synergistic therapeutic outcomes.
Jiayu Zhang +16 more
wiley +1 more source
Molecular Oncology, Volume 20, Issue 11, Page 2569-2583, November 2026.Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source
Advanced Healthcare Materials, Volume 15, Issue 41, 6 November 2026.Engineered red blood cell‐derived extracellular vesicles (eRBCEVs) are synthesized via controlled microfluidic assembly from native RBC lipids, enabling tunable encapsulation of proteins, nucleic acids, nanoparticles, and viral vectors. The platform demonstrates reproducible nanoscale architecture, preserved membrane composition, and functional cargo ...
Chiranth K. Nagaraj +23 more
wiley +1 more source
Advanced Materials for Biologics Delivery to Brain Tumors
Advanced Materials, Volume 38, Issue 61, 2 November 2026.Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng +4 more
wiley +1 more source
American Journal of Hematology, Volume 101, Issue 11, Page 2836-2852, November 2026.ABSTRACT Current treatments for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), rare autoimmune diseases in which autoreactive B cells play a major role, can lead to high response rates; however, for many patients these responses are not durable or maintained after treatment discontinuation.
Matthieu Mahévas +4 more
wiley +1 more source